Hello all! I hope you received our Monthly Newsletter this week. If not, please register for it here: http://visitor.constantcontact.com/manage/optin?v=001mCoOzq0-G5L2S9pHIn9txTTyFThxYdmg. Shandra Botts puts in a great deal of work each month to ensure that the newsletter is professional and arrives in a timely manner. It is packed full of information- from tips from health professionals to stories about successful women with diabetes to updates on all of the great projects DiabetesSisters currently has going on.
While I was at the Roche Social Media Summit and the ADA Scientific Sessions last week, I attended some interesting information sessions and learned about some interesting new products while in the Exhibit Hall. First, I’d like to share some information about a promising alternative to the currently cumbersome glucagon injection kits. The Glucapen is a great alternative because, as we all know, it is not ideal to try to read lengthy instructions during an emergency situation. This device requires only 3 steps and the first step is actually pressing a button to mix the ingredients (so you don’t have to worry about doing it right!).
I also met with Lorraine Stiehl to discuss the latest research in diabetes at the University of California, San Francisco. I’d like to share some information with you in case you are able/willing to participate. Both studies are focused on Type 1 diabetes. The purpose of the first study is to se if a combination therapy (Thymoglobulin and Neulasta) can be used as a possible treatment for people who have established type 1 diabetes. Secondarily, they also want to see if this combination will preserve insulin production. To be involved in this study, you need to have Type 1 diabetes that was diagnosed between 4 months- 2 years ago and you must be between 16-44 years of age. The study will last for two years and reimbursement is available. The other study is also focused on Type 1 diabetes. The study will use an investigational product called Regulatory T Cells (Tregs) to see if they will stop the destruction of insulin-making cells. To be eligible, you must have been diagnosed with Type 1 diabetes within the last two years and be between the age of 18-35. Contact Kathleen Fraser at 415-353-9084 or email@example.com for more information about either of these studies.
Onglyza is the final “new” product I’ll mention. It is made by Bristol-Myers Squibb and Astra Zeneca. It is for the treatment of type 2 diabetes. Specifically, is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amount of insulin produced by the body after meals when blood sugar is high. If you have type 2 diabetes, you may be interested in checking it out.